UNSPSC 51281628: Capreomycin

This classification denotes an antitubercular agent and aminoglycoside antibiotic with the molecular formula C19H30N12O6(R1)(R2), a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 232HYX66HC, more generally known as capreomycin. European Medicines Agency schedules capreomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01028MIG. The term CAPREOMYCIN is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 19 1975, list 5.

UNSPSC 51281628 Capreomycin, a Commodity code, shows minimal relevant recent activity; the cataloged state and local opportunities under this code are mislabeled and do not align with capreomycin procurement. The opportunities posted include naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas HHS Commission), medical and first aid supplies for a fire department (City of Tampa), and generic pharmaceuticals through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations target capreomycin, an injectable antibiotic primarily used in tuberculosis treatment. The code's nominal scope—a specific pharmaceutical product line—appears to see little to no actual state and local government buying activity in the recent solicitation record.

State and local procurement offices do not frequently itemize specialty pharmaceuticals at the commodity level in published notices; when they do appear, they are typically embedded within broader medical supply, pharmacy benefit, or cooperative purchasing contracts rather than solicited as standalone line items. The mislabeling of the recent opportunities suggests either classification error at the source or that capreomycin does not generate sufficient independent procurement volume to warrant dedicated solicitations. Business development professionals should assess whether target customers acquire capreomycin through general pharmaceutical contracts, group purchasing organization (GPO) agreements, or centralized state pharmacy benefit programs rather than through standalone notices tagged to this code.